Global Human Growth Hormone (hGH) Market: Industry Analysis & Outlook (2018-2022)

  • ID: 4486801
  • Report
  • Region: Global
  • 86 pages
  • Koncept Analytics
1 of 5
hGH Market Witnessing Rapid Conversion from Daily Agents to Long-Acting Agents

FEATURED COMPANIES

  • Eli Lilly and Company
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • MORE
Human growth hormone is produced by the pituitary gland and it spurs growth in children and adults. It regulates body fluids, muscle and bone growth and fat metabolism of the body. Growth hormone is important for normal functioning in humans. The deficiency of growth hormone is termed as Growth Hormone Deficiency (GHD) and it can be tackled by administering intramuscular or subcutaneous GH injections on daily basis.

In the coming years, this disorder can be treated by various therapeutics which are currently in their final phase of development. This would change the complete market scenario because at present only daily agents are used to treat GHD. The global human growth hormone market is likely to see strong pipeline of drugs with increased research and development activities, which would spur innovation in the market.

The global human growth hormone market is expected to experience robust growth post the launch of therapeutic drugs, primarily due to increasing patient base, and long-acting hGH formulations in development. However, the market growth is hindered by high R&D expenditures and expensive drug costs.

The report “Global Human Growth Hormone (Hgh) Market: Industry Analysis & Outlook (2018-2022)” analyzes the development of this market along with the market opportunities. The four major players: Novartis Ag, Pfizer Inc., Eli Lilly and Company, and Novo Nordisk A/S have being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global market along with the study of the regional markets.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eli Lilly and Company
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • MORE
1. Market Overview
1.1 Human Growth Hormone
1.2 Physiological Effects of hGH
1.3 GH Deficiency (GHD)
1.4 Recombinant Human Growth Hormone (rhGH)
1.5 hGH Market by Indications

2. Global hGH Market
2.1 Global hGH Market by Value
2.2 Global hGH Market Forecast by Value
2.3 Global hGH Market by Volume
2.4 Global hGH Market Forecast by Volume
2.5 Global hGH Market Share by Indication
2.6 Global hGH Market by Indication
2.6.1 Global Pediatric GHD Market Forecast by Value (2017-2022)
2.6.2 Global Other GHD Market Forecast by Value (2017-2022)
2.7 Global hGH Market by Therapeutics
2.8 Global hGH Market Forecast by Therapeutics
2.9 Global hGH Market by Region

3. Regional Markets
3.1 The US
3.1.1 The US hGH Market Forecast by Value
3.1.2 The US hGH Market by Indication
3.1.3 The US Pediatric GHD Patient Population Forecast
3.1.4 The US Pediatric GHD Patient Population by Type
3.2 Europe
3.2.1 Europe hGH Market Forecast by Value
3.2.2 Europe hGH Market by Indication
3.2.3 Europe Pediatric GHD Patient Population Forecast
3.2.4 Europe Pediatric GHD Patient Population by Type
3.3 Japan
3.3.1 Japan hGH Market Forecast by Value
3.3.2 Japan hGH Market by Indication
3.3.3 Japan Pediatric GHD Patient Population Forecast
3.3.4 Japan Pediatric GHD Patient Population by Type

4. Global Human Growth Hormone Market Opportunity
4.1 VRS-317
4.1.1 VRS-317 - The US Growth Hormone Deficiency Market
4.1.2 VRS-317 - European Union (EU) Growth Hormone Deficiency Market
4.1.3 VRS-317 -Japan Growth Hormone Deficiency Market
4.2 TransCon hGH
4.2.1 TransCon hGH -The US and ROW Growth Hormone Deficiency Market

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Long-Acting hGH Formulations in Development
5.1.2 Increasing Incidence of Cancer and HIV/AIDS
5.1.3 Rise in GDP Per Capita
5.1.4 Increased Spending on Medicines
5.1.5 Increasing Global Healthcare Expenditure
5.2 Trends & Development
5.2.1 Use of TransCon Technology
5.2.2 Development of Auto-Injectors
5.2.3 Rapid Conversion of the Existing Market to Long-Acting Agents
5.3 Challenges
5.3.1 High Cost of Treatment
5.3.2 High R&D Costs
5.3.3 Side Effects of rhGH
5.3.4 Low Share of Biosimilar

6. Competitive Landscape
6.1 Global hGH Market
6.1.1 Global hGH Market Share Volume by Company
6.1.2 Pediatric GHD-Long-Acting Hgh Formulations by Company
6.1.3 Adult GHD-Long-Acting Hgh Formulations by Company
6.2 The US hGH Market

7. Company Profiles
7.1 Novartis AG
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 Pfizer Inc.
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategies
7.3 Eli Lilly and Company
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategies
7.4 Novo Nordisk A/S
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategies

List of Charts
  • hGH Secretion Control
  • hGH’s Physiological Effect
  • hGH Market Segmentation by Indication
  • Global hGH Market by Value (2013-2017)
  • Global hGH Market Forecast by Value (2018-2022)
  • Global hGH Market by Volume (2013-2017)
  • Global hGH Market Forecast by Volume (2018-2022)
  • Global hGH Market Share by Indication (2017)
  • Global Pediatric GHD Market Forecast by Value (2017-2022)
  • Global Other GHD Market Forecast by Value (2017-2022)
  • Global hGH Market Share by Daily Agents (2017)
  • Global hGH Market Forecast by Therapeutics (2028)
  • Global hGH Market by Region (2017)
  • The US hGH Market Forecast by Value (2017-2022)
  • The US hGH Market by Indication (2017)
  • The US Pediatric GHD Patient Population Forecast (2017-2022)
  • The US Pediatric GHD Patient Population by Type (2017)
  • Europe hGH Market Forecast by Value (2017-2022)
  • Europe hGH Market by Indication (2017)
  • Europe Pediatric GHD Patient Population Forecast (2017-2022)
  • Europe Pediatric GHD Patient Population by Type (2017)
  • Japan hGH Market Forecast by Value (2017-2022)
  • Japan hGH Market by Indication (2017)
  • Japan Pediatric GHD Patient Population Forecast (2017-2022)
  • Japan Pediatric GHD Patient Population by Type (2017)
  • Global New Cancer Patients by Volume (2013-2017)
  • Global GDP Per Capita (2013-2017)
  • Global Spending on Medicines (2010-2020)
  • Global Healthcare Expenditure (2013-3017)
  • Percentage of Pediatric & Adult GHD Patients Treated With Growth Hormone (2017/2020)
  • Global hGH Market Share Volume by Company (2017)
  • The US hGH Market Value Share by Company (2017)
  • Novartis AG’s Net Sales Share by Business Segments (2017)
  • Novartis AG’s Net Sales and Net Income (2013-2017)
  • Pfizer Inc.’s Revenue Share by Business Segment (2017)
  • Pfizer Inc.’s Revenue and Net Income (2013-2017)
  • Eli Lilly and Company’s Revenue Share by Region (2017)
  • Eli Lilly and Company’s Revenue and Net Income (2013-2017)
  • Novo Nordisk A/S Net Sales by Business Segment (2017)
  • Novo Nordisk A/S’s Net Sales and Net Profit (2013-2017)
  • Novo Nordisk A/S R&D Expenditure (2015-2017)
List of Tables
  • The US Pediatric & Adult Growth Hormone Deficiency Market of VRS-317 (2019-2023)
  • EU Pediatric & Adult Growth Hormone Deficiency Market of VRS-317 (2019-2023)
  • Japan Pediatric & Adult Growth Hormone Deficiency Market of VRS-317 (2020-2023)
  • The US & ROW Pediatric & Adult Growth Hormone Deficiency Market of TransCon hGH (2020-2023)
  • Long-Acting hGH Formulations in Development Globally (2017)
  • Average Annual Cost of hGH Therapy for Children and Adults
  • Pediatric GHD Phase III Trial Design with Long-Acting hGH Formulations (2017)
  • Adult GHD Phase III Trial Design with Long-Acting hGH Formulations (2017)
  • Project Pipeline in Various Stages of R&D (2017)
  • New Products of Novo Nordisk A/S in Pipeline (2017)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Eli Lilly and Company
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll